The state of Arizona currently has 9 active clinical trials seeking participants for Autism research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
Patterns of Neurodevelopmental Disorders
Recruiting
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
Gender:
All
Ages:
All
Trial Updated:
03/22/2024
Locations: Rossignol Medical Center, Phoenix, Arizona
Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Recruiting
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/06/2024
Locations: Southwest Autism Research & Resource Center, Phoenix, Arizona
Conditions: Irritability Associated With Autism Spectrum Disorder
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
Recruiting
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
03/06/2024
Locations: Southwest Autism Research and Resource Center, Phoenix, Arizona
Conditions: Irritability Associated With Autism Spectrum Disorder
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
All
Ages:
Between 12 years and 45 years
Trial Updated:
02/09/2024
Locations: Southwest Autism Research & Resource Center, Clinical Research, Phoenix, Arizona
Conditions: Autism Spectrum Disorder
Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children
Recruiting
The goal of this clinical study is to learn about the utility and performance of the EarliPoint(™) System: Evaluation for Autism Spectrum Disorder to monitor changes in a child's verbal ability, non-verbal learning, and social disability over time in children ages 15-84 months with autism spectrum disorder or related developmental delays (DD) and in those who are typically developing. The main questions it aims to answer are: To estimate the change in each of the EarliPoint index scores in typ... Read More
Gender:
All
Ages:
Between 15 months and 84 months
Trial Updated:
02/02/2024
Locations: Southwest Autism Research and Resource Center (SARRC), Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Autism, Developmental Delay, Autism, Early Infantile, Autism, Infantile
Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD) For Children Ages 31-84 Months
Recruiting
The goal of this clinical study is to learn about the utility and performance of the EarliPoint System (™): Evaluation for Autism Spectrum Disorder to diagnose and assess autism spectrum disorder (ASD) in children ages 31-84 month (2.5 - 7 years chronological age). The main questions it aims to answer are: To determine the sensitivity and specificity of the EarliPoint device (test) compared to Expert Clinician Diagnosis (ECD) using gold-standard clinical reference assessments in the target age... Read More
Gender:
All
Ages:
Between 31 months and 84 months
Trial Updated:
02/02/2024
Locations: Southwest Autism Research and Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Autism
Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder
Recruiting
The purpose of this study is to determine the effectiveness of folinic acid in the treatment of language problems in children with autism spectrum disorder. Folinic acid, also known as leucovorin, is approved by the U.S. Food and Drug Administration (FDA) to decrease side effects during cancer chemotherapy. Folinic acid may be helpful in treating language problems in children with autism spectrum disorder, but this is not known. Therefore, folinic acid is an investigational new drug for this stu... Read More
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
10/23/2023
Locations: Southwestern Research and Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
Recruiting
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of trea... Read More
Gender:
All
Ages:
Between 30 months and 60 months
Trial Updated:
10/23/2023
Locations: Southwestern Autism Research & Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Language Disorders
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism
Recruiting
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays. Participation will last approximately 26 weeks, from screening... Read More
Gender:
All
Ages:
Between 30 months and 60 months
Trial Updated:
10/23/2023
Locations: Southwestern Research & Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Language Disorders